Pilorge, Sylvain <br/><br/>
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.  [electronic resource] 

 -  American journal of hematology  Apr 2014 
 - 399-403 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.23653  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aminoglycosides--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Compassionate Use Trials<br/>Consolidation Chemotherapy<br/>Cytarabine--administration & dosage<br/>Daunorubicin--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Filgrastim<br/>Gemtuzumab<br/>Granulocyte Colony-Stimulating Factor--therapeutic use<br/>Humans<br/>Immunophenotyping<br/>Kaplan-Meier Estimate<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Leukemia, Myelomonocytic, Acute--drug therapy<br/>Male<br/>Methylprednisolone--administration & dosage<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Nucleophosmin<br/>Recombinant Proteins--therapeutic use<br/>Remission Induction<br/>Salvage Therapy<br/>Thrombocytopenia--blood